Table 2 Percentage of patients from each cohort positive for AT8, GT38, and AV1451 in the sampled brain regions
Control N = 11 | DS/AD N = 9 | TSC N = 10 | FTLD-tau N = 5 | ||
|---|---|---|---|---|---|
AT8 | Entorhinal Cx | 3 (27%) | 9 (100%) | 5 (50%) | 5 (100%) |
BA8 | 0 | 9 (100%) | 5 (50%) | 5 (100%) | |
BA11 | 0 | 9 (100%) | 0 | 4 (80%) | |
GT38 | Entorhinal Cx | 1 (9%) | 8 (90%) | 5 (50%) | 4 (80%) |
BA8 | 0 | 8 (90%) | 5 (50%) | 4 (80%) | |
BA11 | 0 | 8 (90%) | 4 (40%) | 4 (80%) | |
AV1451 | Entorhinal Cx | 3 (27%) | 9 (100%) | 6 (60%) | 5 (100%) |
BA8 | 3 (27%) | 9 (100%) | 6 (60%) | 4 (80%) | |
BA11 | 2 (18%) | 9 (100%) | 5 (50%) | 3 (60%) |